Received May 22, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | — |
late second dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of incomplete course of vaccination in a 55-year-old female patient who received HBV (Engerix B) for prophylaxis. Previously administered products included Engerix B (1st dose received on 08 February 2024, with batch number XS27B and expiry date 17 March 2025). On an unknown date, the patient received the 2nd dose of Engerix B. On an unknown date, an unknown time after receiving Engerix B, the patient experienced incomplete course of vaccination (Verbatim: late second dose). The outcome of the incomplete course of vaccination was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date: 16-MAY-2025 Medical Information Canada transferred a pharmacist that wanted to report an Engerix-B late second dose which led to incomplete course of vaccination. Pharmacist said, can the patient receive Twinrix since the patient wanted to have protection also for Hepatitis A? Which guidance can we have on this topic? Vaccination date, vaccine detail and patient demographics were obtained in this call.